Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 7/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.54 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.49 |
| ▸ | SELE | P16581 | 2/20 | 0.49 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5122794 | 0.84 | ADORA1 (0.54) | PRKCIADORA1TMIGD3HPGDADORA2A | |
| SCHEMBL14975387 | 0.83 | PRKCI (0.61) | PRKCIADORA1TMIGD3HPGDADORA2A | |
| SCHEMBL5813837 | 0.82 | PRKCI (0.66) | PRKCIADORA1ADORA2ASELEVCAM1 | |
| SCHEMBL8338691 | 0.82 | SELE (0.45) | PRKCISELEVCAM1MEN1KMT2A | |
| SCHEMBL5118573 | 0.81 | PRKCI (0.41) | PRKCIADORA1HPGDADORA2AMEN1 | |
| SCHEMBL5123556 | 0.81 | ADORA2A (0.42) | PRKCIADORA1HPGDADORA2AMEN1 | |
| SCHEMBL8187273 | 0.79 | PRKCI (0.44) | PRKCIHPGDSELEVCAM1MEN1 | |
| SCHEMBL7513321 | 0.79 | PRKCI (0.55) | PRKCIMEN1KMT2A | |
| SCHEMBL5129155 | 0.78 | LMNA (0.56) | PRKCIADORA1HPGDADORA2ASELE | |
| SCHEMBL5127958 | 0.78 | SELE (0.47) | PRKCIADORA1TMIGD3HPGDADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1685136-A1 | USE OF THIENOPYRIMIDINES | MERCK PATENT GmbH (DE) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005047292-A1 | USE OF THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 2005-05-26 | — | — | WO | disclosed |
| US-6432950-B1 | ANTICANCER AGENTS; KILLING CANCER CELLS | CELL PATHWAYS | 2002-08-13 | — | — | US | disclosed |
| US-6133271-A | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives | CELL PATHWAYS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-6110920-A | TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-29 | — | — | US | disclosed |
| EP-0920431-A1 | THIENOPYRIMIDINES | MERCK PATENT GmbH (DE) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998006722-A1 | THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | TIE1, DPYD, TK2 | PRKCI 1513/4885ADORA1 1249/4885TMIGD3 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.